Abstract Curcumin is an important molecule found in turmeric plants and has been reported to exhibit some profound anti-inflammatory activities by interacting with several important molecular targets found in the mitogenactivated protein kinase and NF-κβ pathways. As part of our continuing effort to search for new anti-inflammatory agents with better in vitro and in vivo efficacies, we have synthesized a series of new unsymmetrical dicarbonyl curcumin derivatives and tested their effects on prostaglandin E 2 secretion level in interferon-γ/lipopolysaccharide-activated macrophage cells. Among those, five compounds exhibited remarkable suppression on prostaglandin E 2 production with IC 50 values ranging from 0.87 to 18.41 µM. The most potent compound 17f was found to down-regulate the expression of cyclooxygenase-2 mRNA suggesting that this series of compounds could possibly target the mitogenactivated protein kinase signal transduction pathway. Whilst the compound did not affect the expression of the conventional mitogen-activated protein kinases, the results suggest that it could disrupt the phosphorylation and activation of the proteins particularly the c-Jun N-terminal kinases. Finally, the binding interactions were examined using the molecular docking and dynamics simulation approaches.
MEDICINAL CHEMISTRY RESEARCH
Inflammation is an adaptive response that could be triggered by noxious stimuli and conditions for example tissue injury and infection. During inflammation, cells fail to regulate the synthesis of prostaglandin E 2 (PGE 2 ) leading to the excess production and accumulation of the molecule in body. A controlled inflammatory response is good as it provides host defense against infection, tissue-repair response, and adaption to stress and restoration of a homeostatic state. However, the persistence of this inflammatory state has been constantly associated with diseases such as cancer, rheumatoid arthritis, atherosclerosis, and pain. It is known that the inflammatory response is governed by a large range of mediators that form complex regulatory networks. For instance, in the event of infection, endotoxin lipopolysaccharide (LPS) binds to TLR-4 to activate two distinct downstream signaling pathways, the mitogen-activated protein kinase (MAPK) and NF-κβ pathways. These signaling pathways are known to up-regulate the expression of cyclooxygenase (COX)-2, subsequently stimulate the conversion of arachidonic acid to prostaglandin H 2 (PGH 2 ) by COX-2 enzyme. Finally, PGH 2 is transformed to PGE 2 by microsomal prostaglandin E 2 -1 (mPGES-1) to promote inflammatory response (Fig. 1) .
The MAPKs cascades are evolutionary conserved, intracellular signal transduction pathways that respond to various extracellular stimuli and control a large number of essential cellular processes including inflammation process (Thalhamer et al. 2008) . Within each of the cascades, the signal is propagated by sequential phosphorylation and activations of the sequential kinases and eventually leads to the phosphorylation of target regulatory proteins by the MAPK and MAPKAPK components. The MAPKs are generally divided into three major groups: the extracellular signal-regulated kinase 1 and 2 (ERK1 and ERK2), the c-Jun N-terminal kinase (JNK1, JNK2, and JNK3), and the p38 kinases (p38α, p38β, p38γ, and p38δ) (Plotnikov et al. 2011 ). These groups respond to different types of extracellular stimuli. Several studies showed that LPS activates the MAP kinases in monocytes and macrophages (Rao 2001) .
For the past few years, curcumin has attracted considerable attention from the scientific community due to its remarkable biological activities such as antioxidant, antiproliferation, anti-angiogenesis, antitumor, and antiinflammation (Mehta et al. 1997; Notoya et al. 2006; ElAzab et al. 2011; Kant et al. 2014; Wei et al. 2014 ). However, the rapid growth in the interest of using this molecule for therapeutic applications has been held back owing to its poor bioavailability and pharmacokinetic profiles. This eventually hinders its chances of passing the clinical trials in the latter stage of drug development. To overcome this problem, various structure-activity relationship and lead optimization studies have been reported. Notably, most of the studies focused on the modifications of the diketone linker by either masking or rigidify the 1, 3-diketone-enol system with a range of heterocyclic rings. Another strategy is directed at varying the two aromatic rings with different heteroaromatic rings or substituting the methoxy and hydroxyl groups at 3-position and 4-position with other functional groups. The above-mentioned strategies are particularly useful as they prevent the molecule from undergoing extensive phase I and phase II metabolism such as reduction, oxidation, sulfation, and glucuronidation (Pan et al. 1999; Asai and Miyazawa 2000; Ireson et al. 2001; Ireson et al. 2002) .
Numerous studies have shown that symmetrical curcumin analogs/derivatives possessed a variety of biological activities including anti-inflammatory, anti-tyrosinase, and immunomodulatory (Lee et al. 2009; Tham et al. 2010; Tham et al. 2011; Bukhari et al. 2014) . Interestingly, there are evidences that suggest the unsymmetrical form of demethoxycurcumin (Fig. 2 ) could achieve better activity and potency (Sandur et al. 2007; Yang et al. 2010) . For example, the unsymmetrical diarylpentadione 1 (Leong et al. 2014) , diarylpentadienone 2 (Mohd and 2-benzoyl-6-benzylidinecyclohexanone 3 have also been found to actively repress the NO production in RAW 264.7 macrophages (Fig. 2) . Recently, our group has reported a series of unsymmetrical monocarbonyl diarylpentanoids 4 (Mohd Aluwi et al.) that Fig. 1 Release of nitric oxide and PGE 2 via MAPK and NF-κB signaling pathways Fig. 2 Naturally isolated unsymmetrical demethoxycurcumin, synthetic unsymmetrical dicarbonyl, and monocarbonyl curcumin analogs potently inhibit the PGE 2 production in murine RAW264.7 macrophages cell lines. As part of our continuing effort to search for new anti-inflammatory agents, herein we report the synthesis and biological evaluation of a series of unsymmetrical dicarbonyl curcumin analogs as potential anti-inflammatory agents.
Results and discussion

Chemical synthesis
Briefly, the syntheses of 8a-b, 12a-b, and 17a-f were carried out via a series of chemical reactions such as the phenolic esterification, the Baker-Venkataraman rearrangement, the Stork enamine reaction and the aldol condensation. First, the acrylic acid 6 or 10a-b were converted to acyl chlorides by phosphoryl chloride (a chlorinating agent) followed by coupling with the selected 2′-hydroxyacetophenones at room temperature in a catalytic amount of hydrochloric acid in pyridine to furnish the formation of phenolic esters. The phenolic ester intermediates were then subjected to BakerVenkataraman rearrangement by stirring with potassium hydroxide in dimethyl sulfoxide (DMSO) at ambient temperature to furnish the target unsymmetrical dicarbonyl curcumin analogs 8a-b and 12a-b, respectively (Scheme 1).
To initiate the synthesis of compounds 17a-f, cyclohexanone (48 mmol) was reacted with pyrrolidine (48 mmol) in the presence of p-toluenesulfonic acid (1 mmol) to afford N-(1-cyclohexenyl)pyrrolidine, an essential enamine intermediate for benzoylation. The N-(1-cyclohexenyl)pyrrolidine (1 mmol) was then reacted with benzoic anhydride (2 mmol) to obtain the corresponding crude product of 2-benzoylcyclohexanone. Subsequent purification by flash chromatography yielded 2-benzoylcyclohexanone with a conversion rate of 30-40%. The purified 2-benzoylcyclohexanone was then reacted with an equivalent amount of B 2 O 3 to afford the formation of boron complex. The complex obtained was then reacted with 4-methoxybenzaldehyde in the presence of tributyl borate and n-butylamine in ethyl acetate under reflux condition overnight. Finally, the crude product obtained was purified using column chromatography to furnish the target compound. The crystal was grown from hexane:ethyl acetate with ratio 9:1 by slow solvent evaporation (Scheme 2).
Effects of the synthesized compounds on PGE 2 secretion level in LPS/IFN-γ-induced RAW264.7 and human recombinant COX-2 activity Results in Table 1 show that the β-diketone moiety containing compounds (series 8 and series 12) exhibited moderate to strong inhibitory activity on PGE 2 production (58-98%). The inhibition was reduced by approximately three-fold when the proton (8a, IC 50 = 3.11 µM) was substituted with OMe group (8b, IC 50 = 8.19 µM) at para position in the order of H > OMe > OH. Apart from that, elongation of the central carbon linker was not favorable as displayed by compound 12b when the inhibition decreased by approximately six-fold. The presence of halogen groups Scheme 1 Reagents and condition: a POCl 3 , pyridine, r.t., HCl; b KOH, DMSO, r.t (3, 4-Cl) in 12b was also equally poor for the inhibition probably due to its low solubility in the solution.
Since compounds from both series 8 and 12 displayed interesting PGE2 inhibitory activity, we wonder whether the substitution of a more rigid cyclohexanone moiety to the linker would further improve the activity of the compounds under the same condition. In fact, this notion is supported by our previous results that installment of a rigid cyclohexanone moiety in β-diketone linker would improve the activity as well as the chemical and metabolic stabilities of the compounds as compared to curcumin . Within our expectation, compounds 17a-f performed better than the compounds from series 8 and 12.
Overall, the results suggest that the presence of methoxy moiety plays an important part in the activity as shown by 17c (98% with IC 50 = 1.20 µM) and 17f (98% with IC 50 = 0.87 µM). Substitution with halogen group (17a = 87%, 17d = 87% and 17e = 88%) and diethylamine group (17b = 88%) led to a decrease in activity possibly due to low solubility properties. The results were further justified when the inhibition was not affected by cell viability as it did not fall near the tested concentration. Therefore, any inhibition on the production of PGE 2 production as displayed by the compounds could not be attributable to cell cytotoxicity. To test whether these compounds could interrupt with the activity of the terminal enzyme COX-2, we compared the results with the non-selective COX inhibitor, indomethacin. The results revealed that the compounds exhibited weak inhibition on COX-2 while non-active against the COX-1 isoform at 25 µM concentration. Although the compounds were considerably more selective towards COX-2 over COX-1, this result does not justify their strong PGE 2 inhibition profile in cells. Figure 3 depicts the dose-dependent graphs of the most active compound 17f on the inhibition of PGE 2 against RAW 264.7 macrophages cells.
Effect of compound 17f on COX-2 expression in LPSstimulated RAW264.7 macrophages At 2.5 µM concentration, compound 17f exerted inhibitory effect on the up-regulation of COX-2 mRNA (Fig. 4) . This implies that the suppressive activity displayed by the compound is likely due to repression in the COX-2 gene transcription level. Several studies have linked the expression of COX-2 is due to the activation of MAPK pathway. One of the key MAPK members involved is p38α MAPK which is also known as a stress kinase. p38α MAPK then phosphorylates the transcription factors that regulate the COX-2 gene expression. This coincides with our previous study (Tham et al. 2011; Tham et al. 2015 ) that BHMC (a curcumin derivative) also worked by down-regulating the activity of p38α MAPK. One might wonder whether compound 17f could exert similar effect on p38α since both compounds share similar structure. To determine the effect of compound 17f on p38 kinase activity, the inhibitory activity of the compound was tested using off-chip mobility shift assay. Interestingly, the compound did not show any effect on the activity of p38α MAPK even at 10 μM. This suggests that the compound could possibly target a different protein or work on a different inhibitory mechanism.
Inhibition of PGE 2 production from LPS-induced human whole blood
Compound 17f was then evaluated for its effect on the PGE 2 secretion level in LPS-induced human whole blood. The inhibition of PGE 2 production indicated by the concentration of PGE 2 in human whole blood was measured by EIA PGE 2 kit (Cayman). The application of human blood was permitted by the Ethics Committee of Universiti Kebangsaan Malaysia (UKM) with approval number NF-016-2013. This approach has been previously described by Tacconelli et al. (2002) to measure the PGE 2 production inhibitory activity of COX-2 inhibitors (Table 2 ). It has also been claimed to be the best representation of COX activities in circulation and account for the free drug effects, allowing for their binding to plasma proteins and distribution in red blood cells. The result showed that compound 17f able to suppress the PGE 2 production in human whole blood with an IC 50 value of 0.604 µM. Figure 5 depicts the dose-dependent graphs of compound 17f on the inhibition of PGE 2 against human whole blood. The result coincides with the previous report, in which curcumin also exhibited a significant PGE 2 reduction in LPS-human whole blood (Koeberle et al. 2009 ). In fact, the metabolites studies of monocarbonyl curcumin analogs conducted by Snyder and co-workers suggested that the protein binding may serve to protect the curcumin analogs from full metabolism in vivo while allowing it to exert a pharmacological effect by means of slow drug release (Moore et al. 2014 ).
Effects of compound 17f on PGE 2 production against human macrophages U937 and phosphorylation of MAPKs Encouraged by the strong PGE 2 inhibition profile of compound 17f in human whole blood, we further tested the Fig. 3 Effect of compound 17f on PGE 2 production in LPS-stimulated RAW264.7 cells. The cells were co-incubated with LPS (5 µg/mL) and different concentrations of compounds ranging from 0.078 to 5 µM. The supernatants were then collected for the measurement of PGE 2 production. The values are expressed as the means ± SD of three individual samples. P < 0.001 as compared with the LPS-treated macrophages; significant differences between groups were determined using one-way ANOVA test followed by a Dunnett's multiple comparison test. #P < 0.05 solvent control compared with the LPS-treated cells; significant difference was determined using unpaired student'stest (# is not significant) Fig. 4 Reverse transcriptase polymerase chain reaction (PCR) on COX-2 expression effects of compound in human U937 macrophages like monocytes. As expected, 17f showed significant PGE 2 inhibition at 25 µM (97%), 12.5 µM (96%) and 6.25 µM (95%) (Fig. 6) . Furthermore, we examined the effects of 17f upon MAPKs expression. Stimulation of human U937 macrophages like monocyte cells with LPS elicited the level of phosphorylation of ERK, JNK, and p38. Compound 17f moderately suppressed the expression of phosphorylated forms of ERK and p38 while significantly suppressed the expression of phosphorylated forms of JNK. On the other hand, non-phosphorylated forms were not affected by treatment (Fig. 6 ). This is in agreement with the previous report, in which curcumin was more effective in blocking JNK activation as compared to ERK activation (Chen and Tan 1998) . Based on our results and the reported study by Chen and colleague, there is a possibility that compound 17f, which shares a similar structure of curcumin could also potentially bind to JNK and block its activation. COX-2 synthesis has also been shown to be highly dependent upon ERK, JNK, and p38, thus it is plausible that the inhibition of these signaling molecules results in the inhibition of COX-2 expression and PGE 2 production as displayed by compound 17f.
X-ray structural characterization of compound 17f
The accuracy of docking is known to be highly dependent on the initial conformation of the input ligand. Therefore, the crystal of the most active compound 17f (3(E)-3-(4-methoxybenzylidene)-2-(hydroxycyclohex-1-enyl) phenyl methanone) or 6(E)-6-(4-methoxybenzylidene)-2-benzoylcyclohex-1-enol) was grown by slow evaporation from hexane: ethyl acetate (7:3) and was subjected to single crystal X-ray structural investigation. Compound 17f crystallized in monoclinic system with space group a = 16.4896 (10) Å, b = 6.5285(4) Å, c = 15.6878(9) Å, α = 90°, β = 95.038(2)°, γ = 90°, Z = 4, V = 1785.96(17) Å. The crystal system and refinement parameters are shown in Table 3 . To begin with, we hypothesized that compound 17f could inhibit JNK2 activation by stabilizing the loop in a position that does not allow its phosphorylation (Thr183 and Tyr185) by upstream kinases and thus prevent the binding of ATP in the active site. First, the protein crystal structure (PDB ID: JNK2 (3NPC)) was retrieved from http://www. rcsb.org/. The crystal conformation of compound 17f was utilized and docked to the proteins followed by a short 10 ns Fig. 5 Effects of compound 17f on PGE 2 production in LPSstimulated human whole blood. The human whole blood were coincubated with LPS (2 µg/mL) and different concentrations of compounds ranging from 0.39 to 25 µM. The values are expressed as the means ± SD of two individual samples. P < 0.001 as compared with the LPS-treated macrophages; significant differences between groups were determined using one-way ANOVA test followed by a Dunnett's multiple comparison test. #P < 0.05 solvent control compared with the LPS-treated cells; significant difference was determined using unpaired student's-test (ns not significant) (Schmid et al. 2011) . As shown in Fig. 8 , the simulated model converged to the equilibrium state during the simulation. The binding interactions exerted by the compound in the proteins were then examined by decomposing the MM-PBSA binding energy on a per residue basis using g_mmpbsa for the final 5 ns of each simulation (Table 4) . Overall, compound 17f showed a favorable binding energy of −90.419 kJ/mol. This suggests that it could bind to JNK2 spontaneously. The result suggests that the phenyl ring of the compound forms multiple hydrophobic interactions with the "back pocket" residues of JNK2 including Lys55, Ile86, Leu106, Met108, and Leu168, consistent with the results of the cocrystallized ligand, BIRB796. Introduction of polar substituent to the phenyl ring in the next study would be interesting as it enhances the polar interactions in this pocket. Besides, the diketone group forms hydrogen bonds with both Lys55 and Glu73 side chains. However, a longer simulation time is required to observe whether the compound could alter the shape of the activation loop. On the other hand, the methoxyphenyl and cyclohexanone groups occupy the lipophilic pocket (Leu76, Ile85, and Ile86) and form multiple hydrophobic interactions with the adjacent residues in the binding site (Fig. 9) .
ADMET properties prediction of 17f
The ADMET properties of the synthesized compounds were calculated using the standard descriptors protocol implemented in Discovery Studio 3.1 to predict the pharmacokinetic of the compounds when they are administered and pass through the body. The parameters included in the analysis were human intestinal absorption (HIA), plasmaprotein binding (PPB), atom based log P (Alog P98), polar surface area, aqueous solubility, blood brain barrier (BBB) penetration, cytochrome P 450 2D6 (CYP2D6) enzyme inhibition, and hepatotoxicity. All the compounds were predicted to be efficiently absorbed in the human intestine. On the other hand, there is no direct inhibition on cytochrome P 450 for compounds 8b, 12a, and 17f. This implies that these compounds can readily undergo oxidation and hydroxylation in the first phase of metabolism. None of the compounds are hepatotoxic and do not exhibit very high BBB except for compounds 17c and 17f. On the downside, Fig. 6 Effect of compound 17f on a PGE 2 production in LPS-stimulated human U937 macrophages cells. The cells were co-incubated with LPS (5 µg/ mL) and different concentrations of compounds (25, 12.5, and 6.25 µM). The supernatants were then collected for the measurement of PGE 2 production. The values are expressed as the means ± SD of three individual samples. P < 0.001 as compared with the LPS-treated macrophages; significant differences between groups were determined using one-way ANOVA test followed by a Dunnett's multiple comparison test. #P < 0.05 solvent control compared with the LPS-treated cells; significant difference was determined using unpaired student's-test (# is not significant). Effect of 17f on IFN-γ/LPS-induced expression of b phosphorylated p38, c phosphorylated ERK expression and d phosphorylated JNK in IFN-g/LPSinduced human U937 macrophages cells. Protein extracted from cells stimulated with IFN-γ/LPS for 2 h with or without 17f was subjected to Western blot analysis. The western blot is a representative of three independent experiments. The data represent the mean ± SD of three individual sample. P < 0.001 significantly differed from IFN-g/LPS-induced controls these compounds were predicted to exhibit ≥90% of PPB. Overall, the data are summarized in Table 4 .
Conclusion
In summary, compound 17f was found to inhibit the secretion level of PGE 2 in LPS-induced U937 cells by preventing the activation of MAPKs particularly c-Jun Nterminal kinases. The docking computational results suggest that it could bind to the activation loop and stabilize the DFG-out conformation. This has a big implication as it stabilizes the JNK in a conformation that prevents activation by upstream kinases and ATP binding to the active site. To support this, further SAR and MAPK kinase profiling studies need to be carried out in the future.
Materials and methods
Representative synthetic procedures and spectral characterizations
General procedure for the preparation of 8a-b and 12a-b
Phosphoryl chloride (POCl 3 ; 20 mmol) was added slowly to a mixture of the appropriate 2'-hydroxyacetophenone (5 mmol) and acrylic acid (5.5 mmol) in pyridine (30 mL). The flask was placed in an ice bath and the reaction mixture was left overnight, with constant stirring at room temperature. The reaction mixture was then poured into 100 mL cold, dilute HCl followed by extraction with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and concentrated in vacuo. The crude product obtained was further purified by open column chromatography. Ground Table 3 Crystal and structure refinement parameters of 17f 3-hydroxy-1-(2-hydroxyphenyl)-3-phenylprop-2-en-1-one (8a) Yellow amorphous (yield 67%), mp: 78-80°C; 1 H nuclear magnetic resonance (NMR) (600 MHz, CDCl 3 ) δ 15.55 (s, 1H), 12.10 (s, 1H), 7.97-7.92 (m, 1H), 7.79 (dd, J = 8.1, 1.5 Hz, 1H), 7.55 (dd, J = 4.9, 3.7 Hz, 1H), 7.53-7.44 (m, 2H), 7.01 (dd, J = 8.4, 1.0 Hz, 1H), 6.93 (ddd, J = 8.2, 7.2, 1.1 Hz, 1H).
13 C NMR (151 MHz, CDCl 3 ) δ 195. 71, 177.55, 162.51, 135.83, 132.41, 128.79, 128.51, 126.83, 119.09, 119.02, 118.84, 92.32 51, 176.05, 165.94, 165.36, 132.06, 130.13, 128.72, 126.66, 112.65, 107.98, 101.37, 91.99, 55.56 04, 174.47, 162.63, 139.91, 135.81, 135.03, 130.09, 128.98, 128.49, 128.01, 122.18, 119.01, 118.78, 96.98 
General procedure for the preparation of 17a-f
A catalytic amount of p-toluenesulphonic acid was added into a mixture of cyclohexanone (20 mmol) and pyrrolidine (20 mmol) in 30 mL of toluene and the mixture was then refluxed on a Dean and Stark apparatus for 2 h to prepare enamine. Upon completion, 20 mmol of benzoic anhydride in 20 mL of toluene was added dropwise into the reaction solution and stirred for 24 h. Distilled water (10 mL) was then added and further refluxed for 30 min. The resulting reaction mixture was extracted with 3 M HCl and with 20 mL water. The toluene layer was dried over anhydrous magnesium sulphate and concentrated in vacuo to give Atom-based log P (Alog P98) (≤2.0 or P ≥ 0: very low absorption) c Level of human intestinal absorption prediction; 0 (good), 1 (moderate), 2 (poor), 3 (very poor) d The base d 10 logarithm of the molar solubility log (Sw) (25°C, pH = 7.0) (acceptable drug-like compounds:6 < log(Sw) ≤ 0) e Level of aqueous solubility prediction; 0 (extremely low), 1 (very low), 2 (low), 3 (good), 4 (optimal), 5 (too soluble), 6 (warning: molecules with one or more unknown Alog P calculation) f Very high penetrants (log BBP ≥ 7)
g Level blood brain barrier penetration prediction; 0 (very high penetrate), 1 (high), 2 (medium), 3 (low), 4 (undefined) h Prediction plasma-protein binding (0: <90%; 1 ≥ 90%;) I Prediction cytochrome P 450 2D6 enzyme inhibition (0: non-inhibitor; 1: inhibitor) j Prediction hepatotoxicity (0: non-toxic; 1: toxic) crude compound. The crude compound was purified by column chromatography to afford 2-benzoylcyclohexanones. Boron trioxide (1.5 g) was added into a flask containing 10 mL of ethyl acetate in the presence of 2-benzoylcyclohexanone, and stirred at 70°C for 3 h. Appropriate benzaldehyde (20 mmol) and tributyl borate (20 mmol) were then added into the solution and the mixture was stirred for 30 min. Catalytic amount of n-butylamine was added dropwise and stirred for overnight followed by reflux with 10 mL of 1 M HCl for 30 min. The reaction mixture was extracted with ethyl acetate and dried over anhydrous magnesium sulphate. The desired product was purified by column chromatography.
(3-(2,3-dimethoxybenzylidene)-2-hydroxycyclohex-1-en-1-yl)(phenyl)methanone (17c) Yellow amorphous (yield 70%), mp: 68-70°C; 1 H NMR (600 MHz, CDCl 3 ) δ 7.92 (s, 1H), 7.61-7.59 (m, 2H), 7.50-7.43 (m, 3H), 7.09 (t, J = 8.0 Hz, 1H), 6.99-6.95 (m, 1H), 6.94 (dd, J = 8.1, 1.2 Hz, 1H), 3.92 (s, 3H), 3.86 (s, 2H), 2.71-2.64 (m, 2H), 2.58-2.51 (m, 2H), 1.70-1.64 (m, 2H).
13 C NMR (151 MHz, CDCl 3 ) δ 195. 90, 175.95, 152.88, 148.00, 138.47, 133.57, 130.74, 130.52, 128.98, 128.11, 127.56, 123.45, 122.15, 112.47, 108.25, 61.09, 55.89, 27.64, 27.36, 23.66 194.28, 177.50, 159.69, 138.30, 133.39, 131.88, 130.56, 130.45, 128.99, 128.09, 127.66, 113.91, 108.01, 55.34, 27.70, 27.12, 23.60 FBS, 1% (v/v) penicillin G/streptomycin in 5% CO 2 at 37°C. RAW264.7 cells at 80-90% confluency were detached and centrifuged at 1000 RPM in 4°C for 10 min. The cell viability of cultured cells used in the assay was always >95% as determined by trypan blue dye exclusion.
Cell stimulation and treatment RAW264.7 (5 × 10 5 cells/well) were seeded into a tissue culture grade 96-well plate and incubated for 24 h at 37°C, 5% CO 2 for cell attachment. The attached cells were Fig. 9 a The energetic contribution of JNK2 residues in the binding of compound 17f using energy2bfac. b Important amino acid residues in the pocket indicated based on color scale (red = favorable interaction; blue = unfavorable interaction). Energies are given as kJ/mol. c MD simulation snapshots of compound 17f (color figure online) stimulated in 100 U/mL of recombinant interferon (IFN)-γ and 2 µg/mL of LPS with or without presence of test compound at a final volume of 100 µL/well. DMSO was used as vehicle to add test compound into the culture medium and the final concentration of DMSO was 0.1% in all cultures. Cells were then incubated at 37°C, 5% CO 2 for 17-20 h.
Cell viability
The cytotoxicity of test compound on cultured cells was determined by assaying the reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, 5 mg/ mL) to formazan salts. After treatment, the supernatant of each wells were removed followed by addition of 20 µL of MTT reagents into each well. The mixture of culture media and MTT were removed after incubated in 37°C for 4 h and the formazan salts were dissolved by adding 100% DMSO. The absorbance was then measured at 570 nm on a SpectraMax Plus microplate reader (Molecular Devices Inc., Sunnyvale, CA, USA) at room temperature.
Determination of PGE 2
The cell culture supernatants were collected and analyzed for PGE 2 secretion using PGE 2 EIA kits (Cayman Chemical, Ann Arbor, MI, USA). The protocols provided by the manufacturers were followed to the detail. The data was obtained using a SpectraMax Plus microplate reader (Molecular Device, Sunnyvale, CA, USA). The concentration of PGE 2 for each sample was calculated from their respective standard curves.
Cyclooxygenase assay
The effects of the synthesized compounds on COX-1 and COX-2 inhibition were analyzed using COX (ovine/human) inhibitor screening assay kit (Cayman Chemical, Ann Arbor, MI, USA). The protocols provided by the manufacturers were followed to the detail. The data was obtained using a SpectraMax Plus microplate reader (Molecular Device, Sunnyvale, CA, USA). The concentration of PGEs for each sample was calculated from their respective standard curves.
LPS-stimulated mRNA expressions of COX-2 RNA extraction and real-time polymerase chain reaction (RT-PCR)
The total RNA from RAW 264.7 macrophages was isolated and purified using PureLink RNA Mini Kit and PureLink DNase according to the manufacturer's protocol. The quantity and quality of the extracted RNA was analyzed using Infinite 200 PRO NanoQuant (Tecan, Switzerland). The cDNA was prepared from 1.5 mg total RNA by reverse transcription using SuperScript VILO MasterMix for RT-PCR according to the instructions in the manual supplied alongside kit. The cDNA was also quantified using Infinite 200 PRO NanoQuant. The mastermix for rtPCR (KAPA Taq Ready Mix PCR Kit) was purchased from Kappa Biosystems ® (Wilmington, Massachusetts, USA) and the reaction mixture was prepared by adding cDNA, forward and reverse primers and nuclease free water to the mastermix. The realtime-PCR was performed with the following conditions: 95°C for 3 min, followed by 32 cycles at 98°C for 20 s and 60°C for 15 s. For COX-2 gene, the forward and reverse primers were 5′(CTG GTG CCT GGT CTG ATG ATG TAT G)3′ and 5′(TCT CCT ATG AGT ATG AGT CTG CTG GTT)3′. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the endogenous control for normalization. Its forward and reverse primer sequences were 5′ACCACAGTCCATGCCATCAC3′ and 5′TCCACCACCCTGTTGCTGTA3′ respectively. The RT-PCR was carried out in Eppendorf Mastercycler Nexus Gradient Thermal Cycler (Hamburg, Germany). Amplification products were resolved by 1% agarose gel electrophoresis at 90 V for 60 min in TAE (Tris-acetate-EDTA) buffer and visualized by ethidium bromide staining. The images of the gel were taken by an image reader (Fujifilm LAS-3000, Tokyo, Japan). The densitometric analysis was performed using ImageJ software. Up-regulation of COX-2 mRNA in RAW264.7 macrophages was observed after stimulation with LPS.
P38α MAPK assay
Carna Biosciences (http://www.carnabio.com/) determined the p38α inhibitory activity using off-chip mobility shift assay (MSA). The assay used the truncated human p38α [9-352 amino acids of accession number NP_620581.1] expressed as N-terminal Glutathione S-transferase (GST)-fusion protein (66 kDa) using E. coli expression system. Activated GST-p38α was then purified using glutathione sepharose chromatography. The assay used modified erktide as substrate and ATP at 1 mM.
Western blot
Cell extracts and cell culture supernatants were analyzed by Western blot analysis. Two hours after 17f treatment, differentiated cells were treated with LPS (1 µg/mL) for 30 min. The 17f-treated cells were washed twice with PBS and suspended inRIPAlysis buffer and complete protease inhibitor cocktail. Cell suspensions were incubated on ice for 30 min and centrifuged at 16,000×g for 10 min at 4°C. The supernatants of cell suspensions were harvested as described above and stored at −80°C. Total protein concentration was determined using the Bio-Rad Bradford assay. Proteins were separated by electrophoresis in 10% SDSpolyacrylamide gels and transferred into polyvinylidene fluoride membranes. Specific proteins were detected using the appropriate primary and secondary antibodies before visualization using enhanced chemiluminescence and gel documentation system. The results were analyzed by online Image Lab Software.
X-ray crystal structural determination
Single crystal X-ray experiment of 17f was performed on Bruker D-QUEST diffractometer using graphitemonochromated Mo-Kα radiation (λ = 0.71073 Å). Intensity data was measured at 301(2)°K by the ω-scan. Accurate cell parameters and orientation matrix were determined by the least-squares fit of 25 reflections. Intensity data was collected for Lorentz and polarization effects. Empirical absorption correction was performed using multiscan. The structure was solved by direct methods and least-squares refinement of the structure was carried out by the SHELXL-97 program. All the non-hydrogen atoms were refined anisotropically. The hydrogen atoms were placed in calculated positions, allowing them to ride on their parent C atom with Uiso(H) = xUeq(C) where, x = 1.5 for methyl; 1.2 for non-methyl groups, except the hydrogen atoms attached to oxygen atoms were located from Fourier maps and refined isotropically. A summary of the data collections and details of the structure refinement is given in Table 3 . Crystallographic data for the structural determination has been deposited with the Cambridge Crystallographic Data Centre, CCDC No 1487324. This information may be obtained free of charge from the Director, CCDC, 12 Union Road, Cambridge CB2, 1EZ, UK; http://www.ccdccam.ac.uk/ const/retrieving.html).
Molecular dynamics simulation
Compound 17f was docked to the protein crystal structure JNK2 (3NPC) using cDOCKER program implemented in Accelrys Discovery Studio 3.1. The parameterization of ligands was carried out using Automated Topology Builder (ATP) server. Protonation states of ionizable residues were chosen based on their most probable state at pH 7.4. GROMACS was used to prepare the input files for MD simulations. The united-atom GROMOS96 54a7 force field was chosen. The prepared complex structure was then immersed in a 10 Ǻ isomeric truncated octahedral box of pre-equilibrated SPC/E water. The net charge of the system was then neutralized by adding counter ions as required. The ionic strength was adjusted by the addition of 0.1 M of NaCl. MD simulations were performed using the LINCS algorithm to constrain bond lengths and periodic boundary conditions were applied in all directions. Longrange electrostatic forces will be treated using the Fast ParticleMesh Ewald method (PME). Van der Waals forces and Coulomb potential were treated using a cut-off of 0.9 nm and the simulation time step was set to 2 fs. An initial velocity obtained according to a Maxwell distribution at 310 K is given to all the atoms. During the simulation, Berendsen barostat and thermostat were set at 1 bar and 310 K with a coupling time of τP = 2 ps and τT = 0.1 ps, respectively. The production run was set for 10 ns at constant pressure and temperature conditions.
MM-PBSA calculation
A single trajectory approach was adopted in the calculation of the binding free energies between the receptor and inhibitors according to the snapshots taken during the performed MD trajectory. In the MM-PBSA method, the binding free energy (ΔG bind ) could be approximated by summing the average energy of molecular mechanics (ΔE MM ), the solvation free energy (ΔG solv ) (Eisenhaber et al. 1995; Baker et al. 2001; Pronk et al. 2013; Kumari et al. 2014) .
